OncoResponse

8 articles with OncoResponse

• 

  Money on the Move: March 31 – April 6

  4/7/2021

  April springs up with showers of cash for these life sciences companies.

• OncoResponse Raises $40.6 Million Series C Financing

  3/31/2021

  - New capital will fund lead antibody, OR2805, through Phase 1 and 2 clinical studies -  Adds Magnetar Group, Yonjin Ventures and Bering Capital to the syndicate

• OncoResponse Raises $40 Million in Series B Financing

  9/11/2018

  Adds RiverVest Venture Partners, Qatar Investment Authority and Redmile Group to List of Financial Backers

• OncoResponse Expands Scientific Leadership With the Addition of Dr. Anil Singhal as CSO and Dr. Kamal D. Puri as VP, R&D

  1/2/2018

  OncoResponse today announced it has expanded its scientific leadership through the additions of Anil Singhal, Ph.D., and Kamal D. Puri, Ph.D., to the management team.

• OncoResponse Adds Anti-EMP2 Antibody to Oncology Pipeline Through Acquisition of Paganini Biopharma

  11/7/2017

  OncoResponse today announced that it has closed the acquisition of Paganini Biopharma, acquiring all of its assets including an anti-epithelial membrane protein 2 (EMP2) fully human monoclonal antibody, ONCR-201.

• OncoResponse Announces Final Closing Of $22.5M Series A Financing Round

  3/9/2017

• OncoResponse Secures $7 Million In Supplemental Series A Funding

  10/10/2016

• Helsinn Investment Fund To Invest $3.5 Million In OncoResponse

  10/10/2016